A new Phase 3 clinical trial testing Kyverna Therapeutics’ cell therapy candidate KYV-101 in people with myasthenia gravis (MG) — a study the developer says “supports [a] clear and rapid path […] The post ‘FDA-aligned’ trial of KYV-101 for MG likely to start enrolling this year appeared first on Myasthenia Gravis News.
